Literature DB >> 18705633

Cancer incidence among persons with fragile X syndrome in Finland: a population-based study.

R Sund1, E Pukkala, K Patja.   

Abstract

BACKGROUND: Fragile X syndrome is a common inheritable cause of intellectual disability (ID) and is characterised by a large number of CGG repeats at the gene FMR1 located on the X-chromosome. It has been reported that this genetic mechanism may protect against malignant transformations.
METHODS: We extracted from the Finnish registry on persons with ID a cohort of 302 persons with a fragile X diagnosis during 1982-1986. Follow-up for cancer incidence was performed in the Finnish Cancer Registry until the end of the year 2005.
RESULTS: There were 11 reported cancers during the mean follow-up of 21.4 years per person. The expected number of cancers based on the average Finnish population was 13.8 and no statistically significant protective effect was detected [standardised incidence ratios (SIR) 0.80, confidence interval (CI) 95% 0.40-1.4]. An increased risk for lip cancer was found (SIR 23, CI 95% 2.8-85).
CONCLUSIONS: Confirmation of hypotheses about the mechanisms linking FXS and cancer needs further research.

Entities:  

Mesh:

Year:  2008        PMID: 18705633     DOI: 10.1111/j.1365-2788.2008.01116.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  11 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Emergency department and inpatient hospitalizations for young people with fragile X syndrome.

Authors:  Suzanne McDermott; James W Hardin; Julie A Royer; Joshua R Mann; Xin Tong; Orgul D Ozturk; Lijing Ouyang
Journal:  Am J Intellect Dev Disabil       Date:  2015-05

Review 3.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

4.  Cancer Risk in Patients With Fuchs Endothelial Corneal Dystrophy.

Authors:  Timothy T Xu; Keith H Baratz; Michael P Fautsch; David O Hodge; Michael A Mahr
Journal:  Cornea       Date:  2021-09-27       Impact factor: 3.152

5.  Aging in fragile X syndrome.

Authors:  Agustini Utari; Evan Adams; Elizabeth Berry-Kravis; Alyssa Chavez; Felicia Scaggs; Lily Ngotran; Antoniya Boyd; David Hessl; Louise W Gane; Flora Tassone; Nicole Tartaglia; Maureen A Leehey; Randi J Hagerman
Journal:  J Neurodev Disord       Date:  2010-05-12       Impact factor: 4.025

Review 6.  Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.

Authors:  Da-Zhi Liu; Bradley P Ander
Journal:  ScientificWorldJournal       Date:  2012-04-01

7.  Tongue cancer with mental retardation due to microcephaly: a clinical report.

Authors:  Akifumi Enomoto; Takanori Nakatani; Eri Morikage; Takeshi Shimoide; Suguru Hamada
Journal:  World J Surg Oncol       Date:  2015-07-16       Impact factor: 2.754

8.  Intellectual and developmental disabilities: male health.

Authors:  Joav Merrick; Mohammed Morad; Eli Carmeli
Journal:  Front Public Health       Date:  2014-10-24

Review 9.  Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge.

Authors:  Daniel Satgé; Emmanuelle Kempf; Jean-Bernard Dubois; Motoi Nishi; Jean Trédaniel
Journal:  Lung Cancer Int       Date:  2016-09-26

Review 10.  mTOR, a Potential Target to Treat Autism Spectrum Disorder.

Authors:  Atsushi Sato
Journal:  CNS Neurol Disord Drug Targets       Date:  2016       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.